Patents by Inventor Anna M. Wu
Anna M. Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8703920Abstract: The present application provides fully human antibodies against N-Cadherin for therapeutic and diagnostic methods in cancer.Type: GrantFiled: November 9, 2009Date of Patent: April 22, 2014Assignee: The Regents of the University of CaliforniaInventors: Robert E. Reiter, Eric Lepin, Anna M. Wu
-
Publication number: 20140072569Abstract: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.Type: ApplicationFiled: October 28, 2013Publication date: March 13, 2014Applicant: The Regents of The University of CaliforniaInventors: Jonathan BRAUN, Lynn K. Gordon, Kaori Dadgostar, Madhuri Wadehra, Kathleen A. Kelly, Anna M. Wu
-
Publication number: 20140017240Abstract: The present application provides fully human antibodies against N-Cadherin for therapeutic and diagnostic methods in cancer.Type: ApplicationFiled: June 17, 2013Publication date: January 16, 2014Applicant: The Regents of the University of CaliforniaInventors: Robert E. Reiter, Eric Lepin, Anna M. Wu
-
Publication number: 20130344078Abstract: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.Type: ApplicationFiled: August 21, 2013Publication date: December 26, 2013Applicant: The Regents of The University of CaliforniaInventors: Jonathan BRAUN, Lynn K. Gordon, Kaori Shimazaki Dadgostar, Madhuri Wadehra, Kathleen A. Kelly, Anna M. Wu
-
Publication number: 20130230527Abstract: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.Type: ApplicationFiled: November 26, 2012Publication date: September 5, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jonathan BRAUN, Lynn K. Gordon, Kaori Shimazaki, Madhuri Wadehra, Kathy A. Kelly, Anna M. Wu
-
Patent number: 8404817Abstract: Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA.Type: GrantFiled: December 1, 2011Date of Patent: March 26, 2013Assignees: City of Hope, The Regents of the University of CaliforniaInventors: Mark A. Sherman, Anna M. Wu, Robert E. Reiter
-
Patent number: 8378086Abstract: Briefly described, embodiments of this disclosure include polynucleotides that encode mutant Cnidarian luciferases that exhibit modulated properties as compared to the corresponding wild-type luciferases, and the modulated properties include at least one of: modulated stability; enhanced light output; and modulated emission maximum. Embodiments of the present disclosure also include polypeptides or fragments thereof encoded by the polynucleotides, constructs including the polynucleotide, expression cassettes, cells, methods of producing the polynucleotides and polypeptides, antibodies, transgenic cells and/or animals, kits, and the like.Type: GrantFiled: July 31, 2012Date of Patent: February 19, 2013Inventors: Sanjiv S. Gambhir, Andreas M. Loening, Anna M. Wu
-
Patent number: 8318906Abstract: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.Type: GrantFiled: October 8, 2008Date of Patent: November 27, 2012Assignee: The Regents of The University of CaliforniaInventors: Jonathan Braun, Lynn K. Gordon, Kaori Shimizaki, Madhuri Wadegra-Dhawan, Kathy A. Kelly, Anna M. Wu
-
Publication number: 20120295326Abstract: Briefly described, embodiments of this disclosure include polynucleotides that encode mutant Cnidarian luciferases that exhibit modulated properties as compared to the corresponding wild-type luciferases, and the modulated properties include at least one of: modulated stability; enhanced light output; and modulated emission maximum. Embodiments of the present disclosure also include polypeptides or fragments thereof encoded by the polynucleotides, constructs including the polynucleotide, expression cassettes, cells, methods of producing the polynucleotides and polypeptides, antibodies, transgenic cells and/or animals, kits, and the like.Type: ApplicationFiled: July 31, 2012Publication date: November 22, 2012Applicants: The Board of Trustees of the Leland Stanford Junior University, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Sanjiv S. Gambhir, Andreas M. Loening, Anna M. Wu
-
Publication number: 20120283418Abstract: The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.Type: ApplicationFiled: July 20, 2012Publication date: November 8, 2012Applicant: City of HopeInventors: Anna M. Wu, John E. Shively, Andrew A. Raubitschek, Mark A. Sherman, Tove Olafsen
-
Patent number: 8258277Abstract: Briefly described, embodiments of this disclosure include polynucleotides that encode mutant Cnidarian luciferases that exhibit modulated properties as compared to the corresponding wild-type luciferases, and the modulated properties include at least one of: modulated stability; enhanced light output; and modulated emission maximum. Embodiments of the present disclosure also include polypeptides or fragments thereof encoded by the polynucleotides, constructs including the polynucleotide, expression cassettes, cells, methods of producing the polynucleotides and polypeptides, antibodies, transgenic cells and/or animals, kits, and the like.Type: GrantFiled: March 22, 2012Date of Patent: September 4, 2012Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of CaliforniaInventors: Sanjiv S. Gambhir, Andreas M. Loening, Anna M. Wu
-
Publication number: 20120178141Abstract: Briefly described, embodiments of this disclosure include polynucleotides that encode mutant Cnidarian luciferases that exhibit modulated properties as compared to the corresponding wild-type luciferases, and the modulated properties include at least one of: modulated stability; enhanced light output; and modulated emission maximum. Embodiments of the present disclosure also include polypeptides or fragments thereof encoded by the polynucleotides, constructs including the polynucleotide, expression cassettes, cells, methods of producing the polynucleotides and polypeptides, antibodies, transgenic cells and/or animals, kits, and the like.Type: ApplicationFiled: March 22, 2012Publication date: July 12, 2012Applicants: The Regents of the University of California, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Sanjiv S. Gambhir, Andreas M. Loening, Anna M. Wu
-
Patent number: 8173791Abstract: Briefly described, embodiments of this disclosure include polynucleotides that encode mutant Cnidarian luciferases that exhibit modulated properties as compared to the corresponding wild-type luciferases, and the modulated properties include at least one of: modulated stability; enhanced light output; and modulated emission maximum. Embodiments of the present disclosure also include polypeptides or fragments thereof encoded by the polynucleotides, constructs including the polynucleotide, expression cassettes, cells, methods of producing the polynucleotides and polypeptides, antibodies, transgenic cells and/or animals, kits, and the like.Type: GrantFiled: March 24, 2011Date of Patent: May 8, 2012Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of teh University of CaliforniaInventors: Sanjiv S. Gambhir, Andreas M. Loening, Anna M. Wu
-
Publication number: 20120076728Abstract: This invention provides constructs comprising a protein scaffold, wherein the scaffold comprises Domain III, Domain IIIa, or Domain IIIb of human serum albumin or a polypeptide having substantial sequence identity to the Domain III, the Domain IIIa, or the Domain IIIb; and a targeting moiety in covalent linkage to the protein scaffold; and a therapeutic moiety and/or an imaging moiety in covalent linkage to the protein scaffold. The scaffold can be modified to tune the serum pharmacokinetics of the construct. In addition to methods of making the constructs, therapeutic, imaging and diagnostic uses of the constructs are also provided.Type: ApplicationFiled: April 7, 2010Publication date: March 29, 2012Applicant: The Regents of the University of CaliforniaInventors: Anna M. Wu, Vania E. Kenanova, Tove Olafsen
-
Publication number: 20120077962Abstract: Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA.Type: ApplicationFiled: December 1, 2011Publication date: March 29, 2012Inventors: Mark A. SHERMAN, Anna M. Wu, Robert E. Reiter
-
Publication number: 20120020983Abstract: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.Type: ApplicationFiled: October 8, 2008Publication date: January 26, 2012Applicant: The Regents of the University of CaliforniaInventors: Jonathan Braun, Lynn K. Gordon, Kaori Shimazaki, Madhuri Wadehra, Kathy A. Kelly, Anna M. Wu
-
Patent number: 8088908Abstract: Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA.Type: GrantFiled: May 10, 2006Date of Patent: January 3, 2012Assignees: City of Hope, The Regents of the University of CaliforniaInventors: Mark A. Sherman, Anna M. Wu, Robert E. Reiter
-
Patent number: 8043830Abstract: The present invention provides methods of metabolically biotinylating recombinant proteins. Cell lines and specific protein and nucleic acid constructs for use in the methods of the present invention are also provided herein.Type: GrantFiled: January 30, 2009Date of Patent: October 25, 2011Assignee: The Regents of the University of CaliforniaInventors: Bhaswati Barat, Anna M. Wu
-
Publication number: 20110229955Abstract: Briefly described, embodiments of this disclosure include polynucleotides that encode mutant Cnidarian luciferases that exhibit modulated properties as compared to the corresponding wild-type luciferases, and the modulated properties include at least one of: modulated stability; enhanced light output; and modulated emission maximum. Embodiments of the present disclosure also include polypeptides or fragments thereof encoded by the polynucleotides, constructs including the polynucleotide, expression cassettes, cells, methods of producing the polynucleotides and polypeptides, antibodies, transgenic cells and/or animals, kits, and the like.Type: ApplicationFiled: March 24, 2011Publication date: September 22, 2011Applicants: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of CaliforniaInventors: Sanjiv S. Gambhir, Andreas M. Loening, Anna M. Wu
-
Patent number: 7939649Abstract: Briefly described, embodiments of this disclosure include polynucleotides that encode mutant Cnidarian luciferases that exhibit modulated properties as compared to the corresponding wild-type luciferases, and the modulated properties include at least one of: modulated stability; enhanced light output; and modulated emission maximum. Embodiments of the present disclosure also include polypeptides or fragments thereof encoded by the polynucleotides, constructs including the polynucleotide, expression cassettes, cells, methods of producing the polynucleotides and polypeptides, antibodies, transgenic cells and/or animals, kits, and the like.Type: GrantFiled: September 6, 2006Date of Patent: May 10, 2011Assignees: Stanford University, Regents of University of CaliforniaInventors: Sanjiv S. Gambhir, Andreas M. Loening, Anna M. Wu